0
This study analysed whether the lead compound, BPIP, was able to reduce virus replication in infected piglets. The compound, administered in feed, was readily bioavailable and was well tolerated. Eight specific-pathogen-free pigs received a daily dose of 75 mg kg–1 (mixed in feed) for a period of 15 consecutive days, starting 1 day before infection with the CSFV field isolate Wingene. BPIP-treated pigs developed a short, transient viraemia (one animal remained negative) and leukopenia (three animals did not develop leukopenia). Virus titres at peak viraemia (7 days post-infection) were markedly lower ( 1000-fold) than in untreated animals (P=0.00005) and the viral genome load in blood was also significantly lower (P 0.001) in drug-treated animals than in untreated animals over the entire experiment. At the end of the experiment (day 33), no infectious virus was detectable in the tonsils of BPIP-treated animals, although low levels of viral RNA were detected. The inability to isolate infectious virus from the tonsils indicates that the risk of a persistent CSFV infection is negligible. Further optimization of the antiviral potency and bioavailability of this lead compound may result in molecules completely suppressing virus replication. A potent antiviral could potentially be used as a primary control measure against virus spread in case of an outbreak, in addition to present countermeasures.
This study provides the first proof of concept for the prophylaxis/treatment of CSFV infection in pigs.
R. Vrancken, A. Haegeman, J. Paeshuyse, G. Puerstinger, J. Rozenski, M. Wright, M. Tignon, M.-F. Le Potier, J. Neyts and Frank Koenen. Proof of concept for the reduction of classical swine fever infection in pigs by a novel viral polymerase inhibitor. J Gen Virol 90 (2009), 1335-1342.
